These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2424595)

  • 1. Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer.
    De Besi P; Sileni VC; Salvagno L; Tremolada C; Cartei G; Fosser V; Paccagnella A; Peracchia A; Fiorentino M
    Cancer Treat Rep; 1986 Jul; 70(7):909-10. PubMed ID: 2424595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
    Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
    Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy in squamous cell carcinoma of the esophagus using low dose continuous infusion 5-fluorouracil and cisplatin: results of a prospective study.
    Aroori S; Parshad R; Kapoor A; Gupta SD; Kumar A; Chattophadyay TK
    Indian J Cancer; 2004; 41(1):3-7. PubMed ID: 15105572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
    Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. II. Clinical evaluation in cases with higher than T2 stage].
    Sueyama H
    Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1608-18. PubMed ID: 2230444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus.
    Bazarbashi S; Abdelsalam M; Amin T; El-Bassiouni M; Soudy H; Elweshi A; Alhusseiny H; Rehman K; Memon M; Ajarim D
    Chemotherapy; 2008; 54(4):315-22. PubMed ID: 18701820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
    Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH
    Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
    Merlano M; Tatarek R; Grimaldi A; Margarino G; Rosso R
    Cancer Treat Rep; 1985 Sep; 69(9):961-4. PubMed ID: 4040809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.
    Rowland KM; Taylor SG; Spiers AS; DeConti RC; O'Donnell MR; Showel J; Stott PB; Milner LM; Marsh JC
    Cancer Treat Rep; 1986 Apr; 70(4):461-4. PubMed ID: 3698038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preliminary clinical evaluation of continuous infusion of 5-FU and low-dose Cisplatin (LFP) therapy alone and combined with radiation therapy for treatment of advanced or recurrent esophageal cancer].
    Itoh S; Morita S; Ohnishi T; Tsuji A; Takamatsu M; Horimi T
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):233-8. PubMed ID: 11865629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
    Schena M; Barone C; Birocco N; Dongiovanni D; Numico G; Colantonio I; Bertetto O
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):271-6. PubMed ID: 15592837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
    Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
    Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [120-hour continuous 5-FU infusion and cisplatin in the treatment of advanced esophageal carcinoma--clinical analysis of 19 cases].
    Zhang ZH
    Zhonghua Zhong Liu Za Zhi; 1989 Nov; 11(6):474-6. PubMed ID: 2634552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma.
    Spiridonidis CH; Laufman LR; Jones JJ; Gray DJ; Cho CC; Young DC
    Cancer; 1996 Nov; 78(10):2070-7. PubMed ID: 8918399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
    Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.